Skip to main content
Neuland Laboratories Limited. logo

Neuland Laboratories Limited. — Investor Relations & Filings

Ticker · NEULANDLAB ISIN · INE794A01010 LEI · 335800AVHZURTYQ17N08 BSE.NS Manufacturing
Open in API
Filings indexed 947 across all filing types
Latest filing 2024-04-23 Regulatory Filings
Country IN India
Listing BSE.NS NEULANDLAB

About Neuland Laboratories Limited.

https://www.neulandlabs.com

Neuland Laboratories Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and provides comprehensive Custom Manufacturing Solutions (CMS). The company focuses on complex chemistry and high-quality standards, operating state-of-the-art manufacturing facilities that comply with international regulatory requirements, including those of the USFDA and EDQM. Its product portfolio spans diverse therapeutic areas such as cardiovascular, central nervous system, anti-infectives, and antiasthmatics. Neuland supports pharmaceutical companies globally through the entire lifecycle of a drug, from early-stage clinical development to commercial-scale production. By leveraging advanced technical expertise and a robust quality management system, the organization delivers reliable chemical synthesis and process optimization services to both innovator and generic drug manufacturers.

Recent filings

Filing Released Lang Actions
Board Meeting — NEULAND LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 10-May-2024 to consider and approve the Yearly Audited Financial results of the Company for th…
Regulatory Filings
2024-04-23 English
Board Meeting — Financial Results/Dividend
Board/Management Information Classification · 95% confidence The document is a notice of a Board Meeting scheduled to consider and approve audited financial results and recommend a final dividend. It is addressed to stock exchanges and references compliance with SEBI regulations. The document is short (1666 characters) and serves as an announcement of an upcoming board meeting rather than containing any financial results or detailed reports. Therefore, it is not an Annual Report, Earnings Release, or Interim Report. It is also not a report publication announcement since it does not mention the release of a report but rather the scheduling of a meeting. The content fits best under Board/Management Information (MANG) as it relates to the board's meeting and decisions to be made.
2024-04-23 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document is a declaration under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, for the financial year 2023-24. It is a compliance statement regarding encumbrance of shares by the promoter group. The content is a regulatory declaration related to shareholding and takeover regulations, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. The document length is short (2484 characters) and is a formal declaration for regulatory compliance. Therefore, it fits best under Major Shareholding Notification (MRQ), which covers notifications of changes or declarations related to significant share ownership and encumbrances under SEBI regulations.
2024-04-08 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2024. It is addressed to stock exchanges and certifies that details of securities dematerialized/rematerialized have been furnished as required. The document is a compliance certificate related to securities and share transfer regulations, not a financial report, earnings release, or management discussion. It is also relatively short (3113 characters) and does not contain financial statements or detailed analysis. This fits the description of a Regulatory Filing (RNS), which covers regulatory announcements and compliance documents that do not fit other categories.
2024-04-03 English
Change in Director(s)
Board/Management Information Classification · 100% confidence The document is a formal letter addressed to stock exchanges notifying the completion of tenure and cessation of an Independent Director as per SEBI Listing Regulations. It includes details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of changes in board composition. There is no financial data, earnings information, or report attached. The content clearly relates to management/board changes rather than financial results or other report types. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and focused on a management change announcement, confirming this classification.
2024-03-31 English
Credit Rating
Capital/Financing Update Classification · 95% confidence The document is a short letter addressed to stock exchanges, notifying them of a credit rating upgrade and reaffirmation by CRISIL. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is an update on credit rating, which is a financing-related announcement. The document length is only 1096 characters, indicating it is a brief notice rather than a detailed report. Therefore, it fits best under Capital/Financing Update (CAP) category, which covers updates on company financing activities such as credit rating changes.
2024-03-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.